Atlanta Center for Gastroenterology, PC
& Atlanta Endoscopy Center, LTD
Offices of David Rausher, M.D., F.A.C.G., A.G.A.F., and Charles Parrish, M.D.
Patients treated with Inflectra for inflammatory bowel disease (Crohn’s disease or ulcerative colitis) by our physicians are welcome to infuse at our clinic. Please Contact Us if you would like to discuss receiving Inflectra at our clinic. If you are on Inflectra for IBD but are not already a pre-existing patient of the practice, you will need to have a consultation with one of our physicians prior to beginning Inflectra infusions at our clinic.
Inflectra® | Infusion Therapies
A prescription medicine used in adults with:
Moderate to severe ulcerative colitis (UC) when certain other UC medicines have not worked well enough or cannot be tolerated. Inflectra may help to: begin reducing some symptoms, induce and maintain remission, reduce or stop the use of corticosteroids, and improve the way the lining of your large intestine looks to your healthcare provider.
Moderate to severe Crohn's disease (CD) when certain other CD medicines have not worked well enough or cannot be tolerated. Inflectra may help to: begin reducing some symptoms, achieve remission, and reduce or stop the use of corticosteroids.
More - CLICK HERE to learn more on exactly how Inflectra works, and for important safety information regarding Inflectra. CLICK HERE to access the manufacturer's medication guide, and CLICK HERE for some final helpful information regarding Inflectra.
The drug Infliximab (trade names Remicade®, Remsima®, and Inflectra®) is a chimeric monoclonal antibody and used to treat auto-immune disorders. Infliximab reduces the amount of active human tumor necrosis factor alpha (hTNF-α) in the patient by binding to it and preventing it from signaling the receptors for TNF-α on the surface of various cell types. TNF-α is one of the key cytokines that triggers and sustains the inflammatory reactions. Infliximab is used for the treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis. The specificity of this test system is achieved by using a monoclonal antibody named "Peri-1 mAb" for the coating of the microtiter plate. This antibody is specific for Infliximab only (regardless whether Remicade®, Remsima®, or Inflectra®) and does not cross react with other TNF-α catchers. In this context, identification of biomarkers for (non-)response and risk factors for adverse drug reactions relating to serum concentrations and therapeutic drug monitoring of Infliximab would be very helpful. Enzyme immunoassay (ELISA) test kit for the determination of free Infliximab (Remicade®, Remsima®, and Inflectra®) in serum and plasma. The catcher is a highly specific mAb and the detection antibody is a HRP-labeled mAb binding at the Fc part of the drug. This assay design makes sure that there is no cross reactivity with any other TNF-α catcher. This kit is for research use only, not for use in diagnostic procedures.
Immunomodulator and Biologic Therapy:
Traditional IBD treatments include steroids and surgery, both of which may be effective short-term, but are generally unsuccessful in maintaining remission. Significant side effects can also occur with these treatments.
Our Clinic specializes in the delivery of effective, leading-edge medications, including immunomodulator and biologic therapies. Immunomodulators and biologic treatments like Infliximab (Remicade®), Vedolizumab (Entyvio®) and Infliximab-dyyb (Inflectra®), can effectively induce and maintain remission of IBD, while limiting the need for steroids.